A Review of Modern and Traditional Approaches for the Management of Pulmonary Hypertension

Anuradha      Verma; Anshika      Garg; Sultan      Ahmad; Saquib      Haider; Babita      Kumar; Ritu      Chauhan; Manish   K.   Singh; Sambhu   Charan   Mondal
Abstract

Research Problem: Hypertension, either high blood pressure or pulmonary hypertension, both affect the life of patients in many ways.
Research Questions: Does Pulmonary hypertension similar to high blood pressure?
Does it affect old age people or the neonatal age groups also?
What were the reasons for pulmonary hypertension?
Does pulmonary hypertension manageable with modern and traditional drugs?
Literature Review: The purpose of the literature review is to identify the targeted therapy for pulmonary hypertension and also include the plants that may be effective for the management of pulmonary hypertension.
Conclusion: The author has reviewed many targeted drugs that are presently used, and many are in research that was found effective in making the life of patients as normal as possible.
They also reviewed about 15 herbal plants which were found effective in the management of the disease.
As pulmonary hypertension is not treatable, it can only be managed by changing lifestyle and food habits; therefore, the authors emphasized reviewing the traditional approach for the management of pulmonary hypertension.
Graphical Abstract

[1]
McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol  2015; 65(18): 1976-97.
 [http://dx.doi.org/10.1016/j.jacc.2015.03.540] [PMID: 25953750]

[2]
Sonnweber T, Pizzini A, Tancevski I, Löffler-Ragg J, Weiss G. Anaemia, iron homeostasis and pulmonary hypertension: A review. Intern Emerg Med  2020; 15(4): 573-85.
 [http://dx.doi.org/10.1007/s11739-020-02288-1] [PMID: 32040829]

[3]
Sysol JR, Machado RF. Classification and pathophysiology of pulmonary hypertension. Contin Cardiol Educ  2018; 4(1): 2-12.
 [http://dx.doi.org/10.1002/cce2.71]

[4]
Yao L, Yang Y, He G, Ou C, Wang L, Liu K. Global proteomics deciphered novel-function of osthole against pulmonary arterial hypertension. Sci Rep  2018; 8(1): 5556.
 [http://dx.doi.org/10.1038/s41598-018-23775-8] [PMID: 29615702]

[5]
Jasemi SV, Khazaei H, Aneva IY, Farzaei MH, Echeverría J. Medicinal plants and phytochemicals for the treatment of pulmonary hypertension. Front Pharmacol  2020; 11: 145.
 [http://dx.doi.org/10.3389/fphar.2020.00145] [PMID: 32226378]

[6]
Lan N, Massam B, Kulkarni S, Lang C. Pulmonary arterial hypertension: Pathophysiology and treatment. Diseases  2018; 6(2): 38.
 [http://dx.doi.org/10.3390/diseases6020038] [PMID: 29772649]

[7]
Bazan IS, Fares WH. Pulmonary hypertension: Diagnostic and therapeutic challenges. Ther Clin Risk Manag  2015; 11: 1221-33.
 [PMID: 26316767]

[8]
Maron BA, Galiè N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: A review. JAMA Cardiol  2016; 1(9): 1056-65.
 [http://dx.doi.org/10.1001/jamacardio.2016.4471] [PMID: 27851839]

[9]
Ryan J, Dasgupta A, Huston J, Chen KH, Archer SL. Mitochondrial dynamics in pulmonary arterial hypertension. J Mol Med  2015; 93(3): 229-42.
 [http://dx.doi.org/10.1007/s00109-015-1263-5] [PMID: 25672499]

[10]
Woodard TJ, Kim C, Siao FA. Review of the diagnosis and management of pulmonary arterial hypertension. US Pharm  2018; 43(3): HS10-6.

[11]
Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol  2008; 44(1): 14-30.
 [http://dx.doi.org/10.1016/j.yjmcc.2007.09.006] [PMID: 17950310]

[12]
Gomez-Arroyo JG, Farkas L, Alhussaini AA, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol  2012; 302(4): L363-9.
 [http://dx.doi.org/10.1152/ajplung.00212.2011] [PMID: 21964406]

[13]
Bienertova-Vasku J, Novak J, Vasku A. MicroRNAs in pulmonary arterial hypertension: Athogenesis, diagnosis and treatment. J Am Soc Hypertens  2015; 9(3): 221-34.
 [http://dx.doi.org/10.1016/j.jash.2014.12.011] [PMID: 25660363]

[14]
Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: Pathogenesis and clinical management. BMJ  2018; 360: j5492.
 [http://dx.doi.org/10.1136/bmj.j5492] [PMID: 29540357]

[15]
Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol  2017; 14(10): 603-14.
 [http://dx.doi.org/10.1038/nrcardio.2017.84] [PMID: 28593996]

[16]
Xiang L, Li Y, Deng X, Kosanovic D, Schermuly RT, Li X. Natural plant products in treatment of pulmonary arterial hypertension. Pulm Circ  2018; 8(3): 1-20.
 [http://dx.doi.org/10.1177/2045894018784033] [PMID: 29869936]

[17]
Misumi K, Ogo T, Ueda J, et al. Development of pulmonary arterial hypertension in a patient treated with Qing-Dai (Chinese herbal medicine). Intern Med  2019; 58(3): 395-9.
 [http://dx.doi.org/10.2169/internalmedicine.1523-18] [PMID: 30210129]

[18]
Prins KW, Thenappan T. WHO Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. Cardiol Clin  2016; 34(3): 363.
 [http://dx.doi.org/10.1016/j.ccl.2016.04.001] [PMID: 27443134]

[19]
Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med  2016; 4(4): 306-22.
 [http://dx.doi.org/10.1016/S2213-2600(15)00543-3] [PMID: 26975810]

[20]
Kopeć G, Kurzyna M, Mroczek E, et al. Characterization of patients with pulmonary arterial hypertension: Data from the polish registry of pulmonary hypertension (BNP-PL). J Clin Med  2020; 9(1): 173.
 [http://dx.doi.org/10.3390/jcm9010173] [PMID: 31936377]

[21]
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J  2019; 53(1): 1801913.
 [http://dx.doi.org/10.1183/13993003.01913-2018] [PMID: 30545968]

[22]
Barnett CF, Alvarez P, Park MH. Pulmonary arterial hypertension: Diagnosis and treatment. Cardiol Clin  2016; 34(3): 375-89.
 [http://dx.doi.org/10.1016/j.ccl.2016.04.006] [PMID: 27443135]

[23]
Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J  2019; 53(1): 1801904.
 [http://dx.doi.org/10.1183/13993003.01904-2018] [PMID: 30545972]

[24]
Hoeper MM, McLaughlin VV, Dalaan AMA, Satoh T, Galiè N. Treatment of pulmonary hypertension. Lancet Respir Med  2016; 4(4): 323-36.
 [http://dx.doi.org/10.1016/S2213-2600(15)00542-1] [PMID: 26975811]

[25]
Clapp LH, Gurung R. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors. Prostaglandins Other Lipid Mediat  2015; 120: 56-71.
 [http://dx.doi.org/10.1016/j.prostaglandins.2015.04.007] [PMID: 25917921]

[26]
Corris P, Degano B. Severe pulmonary arterial hypertension: Treatment options and the bridge to transplantation. Eur Respir Rev  2014; 23(134): 488-97.
 [http://dx.doi.org/10.1183/09059180.00007214] [PMID: 25445947]

[27]
Saito Y, Nakamura K, Akagi S, et al. Epoprostenol sodium for treatment of pulmonary arterial hypertension. Vasc Health Risk Manag  2015; 11: 265-70.
 [PMID: 25999730]

[28]
Kimura M, Tamura Y, Takei M, et al. Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension. PLoS One  2015; 10(4): e0121894.
 [http://dx.doi.org/10.1371/journal.pone.0121894] [PMID: 25844932]

[29]
Tokunaga N, Ogawa A, Ito H, Matsubara H. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. J Cardiol  2016; 68(6): 542-7.
 [http://dx.doi.org/10.1016/j.jjcc.2015.11.012] [PMID: 27005767]

[30]
Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med  2000; 342(25): 1866-70.
 [http://dx.doi.org/10.1056/NEJM200006223422503] [PMID: 10861321]

[31]
Han X, Zhang Y, Dong L, et al. Treatment of pulmonary arterial hypertension using initial combination therapy of bosentan and iloprost. Respir Care  2017; 62(4): 489-96.
 [http://dx.doi.org/10.4187/respcare.05280] [PMID: 28119496]

[32]
Moreno-Galdó A, Torrent-Vernetta A, de Mir Messa I, et al. Use of inhaled iloprost in children with pulmonary hypertension. Pediatr Pulmonol  2015; 50(4): 370-9.
 [http://dx.doi.org/10.1002/ppul.23044] [PMID: 24729548]

[33]
Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med  2004; 351(16): 1655-65.
 [http://dx.doi.org/10.1056/NEJMra035488] [PMID: 15483284]

[34]
Budev MM, Minai OA, Arroliga AC. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension. Drugs Today  2004; 40(3): 225-34.
 [http://dx.doi.org/10.1358/dot.2004.40.3.820086] [PMID: 15148531]

[35]
Hill NS, Preston IR, Roberts KE. Inhaled therapies for pulmonary hypertension. Respir Care  2015; 60(6): 794-805.
 [http://dx.doi.org/10.4187/respcare.03927] [PMID: 26070575]

[36]
 Remodulin® (treprostinil sodium) injection. 2015. Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021272s009lbl.pdf

[37]
Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: A therapeutic review. Drug Des Devel Ther  2012; 6: 19-28.

[38]
Lian TY, Jiang X, Jing ZC. Riociguat: A soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Des Devel Ther  2017; 11: 1195-207.
 [http://dx.doi.org/10.2147/DDDT.S117277] [PMID: 28458514]

[39]
Sulica R, Fenton R, Cefali F. Early observations on the use of riociguat in a large, metropolitan pulmonary arterial hypertension/chronic thromboembolic pulmonary hypertension treatment center. Cardiol Ther  2015; 4(2): 209-18.
 [http://dx.doi.org/10.1007/s40119-015-0046-y] [PMID: 26411969]

[40]
Makowski CT, Rissmiller RW, Bullington WM. Riociguat: A novel new drug for treatment of pulmonary hypertension. Pharmacotherapy  2015; 35(5): 502-19.
 [http://dx.doi.org/10.1002/phar.1592] [PMID: 26011143]

[41]
Frank H, Ruber K, Mlczoch J, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest  1997; 112(3): 714-21.
 [http://dx.doi.org/10.1378/chest.112.3.714] [PMID: 9315805]

[42]
Frank H, Gurtner HP, Kneussl M, Lang I, Mlczoch J. [Aminorexinduced, plexogenic pulmonary arteriopathy: 25 years later!]. Z Kardiol  1993; 82(9): 568-72.
 [PMID: 7901949]

[43]
Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood  2010; 115(1): 15-20.
 [http://dx.doi.org/10.1182/blood-2009-09-241851] [PMID: 19880491]

[44]
Masuda Y, Miyazaki H, Kondoh M, et al. Two different forms of endothelin receptors in rat lung. FEBS Lett  1989; 257(2): 208-10.
 [http://dx.doi.org/10.1016/0014-5793(89)81535-2] [PMID: 2555216]

[45]
Migneault A, Sauvageau S, Villeneuve L, et al. Chronically elevated endothelin levels reduce pulmonary vascular reactivity to nitric oxide. Am J Respir Crit Care Med  2005; 171(5): 506-13.
 [http://dx.doi.org/10.1164/rccm.200403-340OC] [PMID: 15579730]

[46]
Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev  2006; 24(1): 63-76.
 [http://dx.doi.org/10.1111/j.1527-3466.2006.00063.x] [PMID: 16939634]

[47]
El-Saber Batiha G, Magdy Beshbishy A, G Wasef L, et al. Chemical constituents and pharmacological activities of garlic (Allium sativum L.): A review. Nutrients  2020; 12(3): 872.
 [http://dx.doi.org/10.3390/nu12030872] [PMID: 32213941]

[48]
Tung NH, Hung LQ, Van Oanh H, et al. Bioactive phenolic compounds from the roots of danshen (Salvia miltiorrhiza). Natural Product Communications  2018; 13(10): 1305-7.

[49]
Hussein HJ, Hameed IH, Hadi MY. Review: Anti-microbial, anti-inflammatory effect and cardiovascular effects of garlic: Allium sativum. Res J Pharm Tech  2017; 10(11): 4069-78.
 [http://dx.doi.org/10.5958/0974-360X.2017.00738.7]

[50]
Park BM, Chun H, Chae SW, Kim SH. Fermented garlic extract ameliorates monocrotaline-induced pulmonary hypertension in rats. J Funct Foods  2017; 30: 247-53.
 [http://dx.doi.org/10.1016/j.jff.2017.01.024]

[51]
Meghwani H, Prabhakar P, Mohammed S, et al. Beneficial effect of Ocimum sanctum (Linn.) against monocrotaline-induced pulmonary hypertension in rats. Medicines  2018; 5(2): 34.
 [http://dx.doi.org/10.3390/medicines5020034] [PMID: 29673152]

[52]
Sharma V, Chanda D. Ocimum: The Holy Basil against Cardiac Anomalies in the ocimum Genome.  Cham: Springer 2018; pp. 25-36.
 [http://dx.doi.org/10.1007/978-3-319-97430-9_3]

[53]
Kashif M, Ullah S. Chemical composition and minerals analysis of Hippophaerhamnoides, Azadirachta indica, Punica granatum and Ocimum sanctum leaves. World J Dairy Food Sci  2013; 8(1): 67-73.

[54]
Arora TK, Arora AK, Sachdeva MK, Rajput SK, Sharma AK. Pulmonary hypertension: Molecular aspects of current therapeutic intervention and future direction. J Cell Physiol  2018; 233(5): 3794-804.
 [http://dx.doi.org/10.1002/jcp.26191] [PMID: 28926093]

[55]
Lei XL, Chiou GC. Cardiovascular pharmacology of Panax notoginseng (Burk) F.H. Chen and Salvia miltiorrhiza. Am J Chin Med  1986; 14(3-4): 145-52.

[56]
Su CY, Ming QL, Rahman K, Han T, Qin LP. Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology. Chin J Nat Med  2015; 13(3): 163-82.
 [http://dx.doi.org/10.1016/S1875-5364(15)30002-9] [PMID: 25835361]

[57]
Yuan T, Chen Y, Zhang H, Fang L, Du G. Salvianolic acid A, a component of Salvia miltiorrhiza, attenuates endothelial–mesenchymal transition of HPAECs induced by hypoxia. Am J Chin Med  2017; 45(6): 1185-200.
 [http://dx.doi.org/10.1142/S0192415X17500653] [PMID: 28893092]

[58]
Rout SK, Dutta S, Sengupta M, Das S, Rout B. Antihypertensive therapy: The concepts of management with herbal and synthetic agents for pulmonary hypertension. Int J Pharm Sci Rev Res  2010; 3(2)

[59]
Ahmadipour B, Kalantar M, Hosseini SM. Hawthorn (Crataegus oxyacantha) Flavonoid extract as an effective medicinal plant derivative to prevent pulmonary hypertension and heart failure in broiler chickens. Kafkas Univ Vet Fak Derg  2019; 25(3): 321-8.

[60]
Ahmadipour B, Kalantar M, Schreurs NM, et al. Flavonoid bioactive compounds of hawthorn extract can promote growth, regulate electrocardiogram waves, and improve cardiac parameters of pulmonary hypertensive chickens. Poult Sci  2020; 99(2): 974-80.
 [http://dx.doi.org/10.1016/j.psj.2019.10.022] [PMID: 32036989]

[61]
Isanga J, Zhang GN. Soybean bioactive components and their implications to health-a review. Food Rev Int  2008; 24(2): 252-76.
 [http://dx.doi.org/10.1080/87559120801926351]

[62]
Matori H, Umar S, Nadadur RD, et al. Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension  2012; 60(2): 425-30.
 [http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.191445] [PMID: 22753213]

[63]
Chen Y, Chen D, Liu S, et al. Systematic elucidation of the mechanism of genistein against pulmonary hypertension via network pharmacology approach. Int J Mol Sci  2019; 20(22): 5569.
 [http://dx.doi.org/10.3390/ijms20225569] [PMID: 31703458]

[64]
Yang Y, Gao M, Wu Z, Guo Y. Genistein attenuates low temperature induced pulmonary hypertension in broiler chicks by modulating endothelial function. Eur J Pharmacol  2010; 649(1-3): 242-8.
 [http://dx.doi.org/10.1016/j.ejphar.2010.09.002] [PMID: 20854807]

[65]
Ahmadipour B, Khajali F. Expression of antioxidant genes in broiler chickens fed nettle (Urtica dioica) and its link with pulmonary hypertension. Anim Nutr  2019; 5(3): 264-9.
 [http://dx.doi.org/10.1016/j.aninu.2019.04.004] [PMID: 31528728]

[66]
Chiang HM, Chen HC, Wu CS, Wu PY, Wen KC. Rhodiola plants: Chemistry and biological activity. J Food Drug Anal  2015; 23(3): 359-69.

[67]
Chen M, Cai H, Yu C, et al. Salidroside exerts protective effects against chronic hypoxia-induced pulmonary arterial hypertension via AMPKα1-dependent pathways. Am J Transl Res  2016; 8(1): 12-27.
 [PMID: 27069536]

[68]
Huang X, Zou L, Yu X, et al. Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway. J Mol Cell Cardiol  2015; 82(82): 153-66.
 [http://dx.doi.org/10.1016/j.yjmcc.2015.03.005] [PMID: 25772255]

[69]
Venkitasamy C, Zhao L, Zhang R, Pan Z. Integrated processing technologies for food and agricultural by-products.  Amsterdam: Elsevier 2019; pp. 181-216.

[70]
Shao J, Wang P, Liu A, Du X, Bai J, Chen M. Punicalagin prevents hypoxic pulmonary hypertension via anti-oxidant effects in rats. Am J Chin Med  2016; 44(4): 785-801.
 [http://dx.doi.org/10.1142/S0192415X16500439]

[71]
Nik AB, Vazifedoost M, Didar Z, Hajirostamloo B. The antioxidant and physicochemical properties of microencapsulated bioactive compounds in Securigera securidaca (L) seed extract by co-crystallization Food Quality and Safety.  Oxford: Academic 2019; p. 25.

[72]
Ahmadipour B. Securigera securidaca seed medicinal herb supplementation of diets improves pulmonary hypertensive response in broiler chickens reared at high altitude. J Anim Physiol Anim Nutr  2018; 102(6): 1601-7.
 [http://dx.doi.org/10.1111/jpn.12981] [PMID: 30155919]

[73]
Wruss J, Waldenberger G, Huemer S, et al. Compositional characteristics of commercial beetroot products and beetroot juice prepared from seven beetroot varieties grown in Upper Austria. J Food Compos Anal  2015; 42: 46-55.
 [http://dx.doi.org/10.1016/j.jfca.2015.03.005]

[74]
Clifford T, Howatson G, West D, Stevenson E. The potential benefits of red beetroot supplementation in health and disease. Nutrients  2015; 7(4): 2801-22.
 [http://dx.doi.org/10.3390/nu7042801] [PMID: 25875121]

[75]
Domínguez R, Cuenca E, Maté-Muñoz J, et al. Effects of beetroot juice supplementation on ardiorespiratory endurance in athletes. A systematic review. Nutrients  2017; 9(1): 43.
 [http://dx.doi.org/10.3390/nu9010043] [PMID: 28067808]

[76]
Singh B, Hathan BS. Chemical composition, functional properties and processing of beetroot-a review. Int J Sci Eng Res  2014; 5(1): 679-84.

[77]
Webb AJ, Patel N, Loukogeorgakis S, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension  2008; 51(3): 784-90.
 [http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.103523] [PMID: 18250365]

[78]
Siervo M, Lara J, Ogbonmwan I, Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: A systematic review and meta-analysis. J Nutr  2013; 143(6): 818-26.
 [http://dx.doi.org/10.3945/jn.112.170233] [PMID: 23596162]

[79]
Wei F, Tanokura M. Organic compounds in green coffee beansCoffee in health and disease prevention.  Massachusetts: Academic Press 2015; pp. 149-62.
 [http://dx.doi.org/10.1016/B978-0-12-409517-5.00017-6]

[80]
Li QY, Zhu YF, Zhang M, et al. Chlorogenic acid inhibits hypoxia-induced pulmonary artery smooth muscle cells proliferation via c-Src and Shc/Grb2/ERK2 signaling pathway. Eur J Pharmacol  2015; 751: 81-8.
 [http://dx.doi.org/10.1016/j.ejphar.2015.01.046] [PMID: 25666384]

[81]
Lisa J. Biotechnology of Fruit and Nut Crops (Biotechnology in Agriculture Series). Washington. Amazon  2020; 29: 703.

[82]
Prior RL, Cao G, Martin A, et al. Antioxidant capacity as influenced by total phenolic and anthocyanin content, maturity, and variety of Vaccinium species. J Agric Food Chem  1998; 46(7): 2686-93.
 [http://dx.doi.org/10.1021/jf980145d]

[83]
Taruscio TG, Barney DL, Exon J. Content and profile of flavanoid and phenolic acid compounds in conjunction with the antioxidant capacity for a variety of northwest Vaccinium berries. J Agric Food Chem  2004; 52(10): 3169-76.
 [http://dx.doi.org/10.1021/jf0307595] [PMID: 15137871]

[84]
Wu X, Kang J. Blueberries: Major phytochemicals and potential health effects in cardiovascular diseasesBerries: Properties, Consumption and Nutrition.  New York, NY, USA: Nova Biomedical Books 2012; pp. 83-104.

[85]
Howard L, Hagar T. Berry fruit phytochemicalsBerry Fruit: Value Added Products for Health Promotion.  Boca Raton, FL, USA: CRC Press 2007; pp. 73-105.

[86]
Gao L, Mazza G. Quantitation and distribution of simple and acylatedanthocyanins and other phenolics in blueberries. J Food Sci  1994; 59(5): 1057-9.
 [http://dx.doi.org/10.1111/j.1365-2621.1994.tb08189.x]

[87]
Türck P, Salvador IS, Campos-Carraro C, et al. Blueberry extract improves redox balance and functional parameters in the right ventricle from rats with pulmonary arterial hypertension. Eur J Nutr  2022; 61(1): 373-86.
 [http://dx.doi.org/10.1007/s00394-021-02642-9] [PMID: 34374852]

[88]
Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res  2008; 22(8): 999-1012.
 [http://dx.doi.org/10.1002/ptr.2399] [PMID: 18618524]

[89]
Abd El-Wahab AE, Ghareeb DA, Sarhan EEM, Abu-Serie MM, El Demellawy MA, El Demellawy MA. In vitro biological assessment of berberis vulgaris and its active constituent, berberine: Antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. BMC Complement Altern Med  2013; 13(1): 218.
 [http://dx.doi.org/10.1186/1472-6882-13-218] [PMID: 24007270]

[90]
Dermarderosian A, Beutler JA. Review of natural products: The most complete source of natural product information. Philadelphia: Lippincott Williams & Wilkins 2001.

[91]
Fatehi M, Saleh TM, Fatehi-Hassanabad Z, Farrokhfal K, Jafarzadeh M, Davodi S. A pharmacological study on Berberis vulgaris fruit extract. J Ethnopharmacol  2005; 102(1): 46-52.
 [http://dx.doi.org/10.1016/j.jep.2005.05.019] [PMID: 15993555]

[92]
Chun YT, Yip TT, Lau KL, Kong YC, Sankawa U. A biochemical study on the hypotensive effect of berberine in rats. Gen Pharmacol  1979; 10(3): 177-82.
 [http://dx.doi.org/10.1016/0306-3623(79)90085-5] [PMID: 572797]

[93]
Marin - NETO JA. Maciel BC, Secches AL, Gallo L. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin Cardiol  1988; 11(4): 253-60.
 [http://dx.doi.org/10.1002/clc.4960110411] [PMID: 3365876]

[94]
Fatehi-Hassanabad Z, Jafarzadeh M, Tarhini A, Fatehi M. The antihypertensive and vasodilator effects of aqueous extract from Berberis vulgaris fruit on hypertensive rats. Phytother Res  2005; 19(3): 222-5.
 [http://dx.doi.org/10.1002/ptr.1661]

[95]
Mahdavi N, Joukar S, Najafipour H, Asadi-Shekaari M. The promising effect of barberry (Zereshk) extract against experimental pulmonary microvascular remodeling and hypertension: A comparison with sildenafil. Pharm Biol  2016; 54(3): 509-15.
 [http://dx.doi.org/10.3109/13880209.2015.1050676] [PMID: 26023989]

[96]
Collins JK, Wu G, Perkins-Veazie P, et al. Watermelon consumption increases plasma arginine concentrations in adults. Nutrition  2007; 23(3): 261-6.
 [http://dx.doi.org/10.1016/j.nut.2007.01.005] [PMID: 17352962]

[97]
 Publications and Information Directorate, CSIR. “The Wealth of India. Raw Materials". 1992. Available From: https://www.scirp.org/(S(i43dyn45teexjx455qlt3d2q))/reference/ReferencesPapers.aspx?ReferenceID=957500

[98]
Fursa TB. Intraspecific classification of water-melon under cultivation. Kulturpflanze  1981; 29(1): 297-300.
 [http://dx.doi.org/10.1007/BF02014757]
Cite As
Current Traditional Medicine

A Review of Modern and Traditional Approaches for the Management of Pulmonary Hypertension

Abstract

Graphical Abstract
